Radius Health (NASDAQ:RDUS) will be posting its Q1 quarterly earnings results before the market opens on Wednesday, May 8th. Analysts expect Radius Health to post earnings of ($0.95) per share for the quarter. Radius Health has set its FY 2019 guidance at EPS.Individual that are interested in participating in the company’s earnings conference call can do so using this link.
Radius Health (NASDAQ:RDUS) last posted its quarterly earnings results on Thursday, February 28th. The biopharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.22) by $0.32. The business had revenue of $34.42 million for the quarter, compared to analysts’ expectations of $33.99 million. Radius Health had a negative return on equity of 168.62% and a negative net margin of 223.03%. On average, analysts expect Radius Health to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
Radius Health stock opened at $22.13 on Tuesday. The stock has a market capitalization of $1.00 billion, a P/E ratio of -4.53 and a beta of 0.98. Radius Health has a 12-month low of $12.81 and a 12-month high of $34.02. The company has a current ratio of 5.92, a quick ratio of 5.79 and a debt-to-equity ratio of 2.97.
In other Radius Health news, Director Willard H. Dere sold 1,680 shares of the firm’s stock in a transaction dated Tuesday, April 16th. The stock was sold at an average price of $22.22, for a total transaction of $37,329.60. Following the transaction, the director now owns 8,620 shares in the company, valued at $191,536.40. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Jessica Hopfield bought 12,800 shares of Radius Health stock in a transaction on Tuesday, March 5th. The shares were bought at an average price of $19.23 per share, for a total transaction of $246,144.00. Following the acquisition, the director now owns 12,800 shares of the company’s stock, valued at approximately $246,144. The disclosure for this purchase can be found here. 4.00% of the stock is currently owned by company insiders.
Several equities analysts recently issued reports on the company. Zacks Investment Research cut Radius Health from a “hold” rating to a “sell” rating in a report on Thursday, January 17th. ValuEngine upgraded Radius Health from a “sell” rating to a “hold” rating in a report on Monday, April 1st. HC Wainwright assumed coverage on Radius Health in a report on Thursday, February 14th. They issued a “neutral” rating and a $22.00 price target on the stock. Finally, BidaskClub upgraded Radius Health from a “hold” rating to a “buy” rating in a report on Friday, April 5th. Five equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $38.00.
TRADEMARK VIOLATION NOTICE: This news story was published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.thelincolnianonline.com/2019/05/07/radius-health-rdus-to-release-earnings-on-wednesday.html.
Radius Health Company Profile
Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator to treat breast cancer.
Read More: Calculate Your Return on Investment (ROI)
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.